Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3022855 with Durvalumab or Tremelimumab in Advanced Solid Tumors
NCT02718911Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of LY3022855 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and ovarian cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose. Started Jun 2016; status: completed.
02
Drugs
LY3022855
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT02718911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718911.